RxDoctor Payments Data

Janaye Keifer, NP

Acute Care · South Bend, INNPI 1669982104

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (47.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Novartis at 55.6% of the total.

$2,696in general payments, 2019–2025

Across 75 payments — averaging $35.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Incyte Corporation$264
  • Genentech USA, Inc.$200
  • Bard Peripheral Vascular, Inc.$124
  • E.r. Squibb & Sons, L.L.C.$119
  • Johnson & Johnson$71
  • plus $420 from 15 others

What the payments were for

  • Food & beverage$1,23846%
  • Education$1787%
  • Other$1,28047%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,696 in reported general payments places this provider in the 85th percentile of 240 acute care providers in Indiana.

See all acute care providers in Indiana

Medicare billing

Part B allowed, 2024
$8,495
Medicare patients
54
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban18$9,594
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$889
Anagrelide Hcl11$793
Acyclovir37$482
Hydroxyurea32$416
Letrozole32$408
Anastrozole14$378
Dexamethasone19$340
Gabapentin12$157
Oxycodone Hcl11$146
Allopurinol17$128
Prednisone14$86
Montelukast Sodium12$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$71$9,59418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 240 acute care providers in Indiana.

Other acute care in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →